drugset / Trial / NCT06347198
Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer
Phase 0
Unknown
30 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Huazhong University of Science and Technology · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a single-center exploratory clinical study to explore the efficacy and safety of Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer.
Timeline
- Start
- 2024-04-10
- Primary completion
- 2024-12-01
- Completion
- 2025-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Inulin | Other / unclassified | 10 g | Oral |
| Background | Fruquintinib | Small molecule | 4 mg | Oral |
| Background | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |